Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
TOKYO, Jul 9, 2020 – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co.,…
Veea and Totalplay Advance Commercial Plans for Secure, AI-Powered Business Services in Mexico
Building An AM Quality Data Backbone That Makes AI Credible
Visionstate Announces $750,000 financing to Support International Expansion and Strategic Growth
Local AI Registry Launches First Public Registry of AI Business Recommendations
Agereh Technologies to Attend 2026 ACI-NA Annual Conference & Exhibition in Philadelphia